Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis.
Bracco Gartner TCL, Crnko S, Leiteris L, van Adrichem I, van Laake LW, Bouten CVC, Goumans MJ, Suyker WJL, Sluijter JPG, Hjortnaes J.
Bracco Gartner TCL, et al. Among authors: suyker wjl.
Front Cardiovasc Med. 2022 Mar 11;9:854314. doi: 10.3389/fcvm.2022.854314. eCollection 2022.
Front Cardiovasc Med. 2022.
PMID: 35360018
Free PMC article.